GENEDX ALERT: Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - GeneDx Holdings Corp. is under investigation for potential violations of federal securities laws and unlawful business practices, following allegations of widespread fraud and revenue inflation tactics [1][2]. Group 1: Allegations and Investigations - Grizzly Research published a report claiming that GeneDx's growth is largely an illusion, driven by fraudulent schemes aimed at exploiting Medicaid and Medicare systems to inflate revenue [2]. - The report alleges that GeneDx has engaged in "code stacking," allowing the company to bill insurance providers for services that do not meet required criteria [2]. - Testimonies from former employees and ongoing litigation suggest that the company's executives, including CEO Katherine Stueland and CFO Kevin Feeley, have sold shares immediately upon vesting, indicating potential insider knowledge of imminent risks [2]. Group 2: Market Reaction - Following the release of the Grizzly report, GeneDx's stock price fell by $4.84 per share, or 6.72%, closing at $67.18 per share on February 5, 2025 [2]. Group 3: Legal Representation - Bragar Eagel & Squire, P.C. is representing GeneDx stockholders in the investigation and is seeking information from those who have suffered losses or have relevant information regarding the claims [1][3].